2025 Q4 -tulosraportti
Vain PDF
12 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 105 | - | - | ||
| 210 | - | - | ||
| 2 035 | - | - | ||
| 34 | - | - | ||
| 1 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenJust a clip from GPT with the question: can this end in acquisition within 6 months? Short answer: 👉 Yes, this can absolutely end in acquisition 👉 Within 6 months? Possible – but not the most likely without a trigger Let's be completely honest and a bit brutally realistic, as you like it: ⸻ 🧠 Why this CAN become an acquisition What you have here hits several “acquisition signals” Big Pharma looks for: 1. Platform, not just one product * circVec works in heart, CNS, eye * Can be plugged into many pipeline projects 👉 This is exactly what companies like Roche, Novartis and Pfizer buy ⸻ 2. Solves a real problem (AAV dose) * Dose is the #1 issue in gene therapy (toxicity + cost) * Here they show: * 10–60x better effect * Lower dose 👉 This is “holy grail”-type improvement ⸻ 3. Preclinical data is starting to be “too good to ignore” * Consistent across tissues * Better than mRNA-based AAV solutions 👉 This is often the point where: * partnerships start * or acquisitions are considered
·1 t sitten · MuokattuVery good abstract and it exudes confidence and trust in the data between the lines. I believe this 'powder' will be supplemented with updated heart 4.0 and CNS data at the presentations themselves. "2 inner and away with them."
·1 t sittenIf people don't open their eyes now, there must be something wrong with their cognitive abilities. Surprisingly, the abstracts are bringing us closer and closer to an acquisition. In my view, this is clearly stronger than many seem to understand. Circio is coming to ASGCT with two abstracts: one oral presentation and one poster. The most important thing is not just that they have been selected. The most important thing is what they actually show. The oral presentation is about circVec as a broad AAV platform across eye, heart, and CNS. This is where the platform case lies. If a technology only works in one narrow model, its value is limited. But when the same principle shows effect in multiple tissues, with different setups and administration routes, it starts to resemble something far more valuable. The eye part is particularly strong: over 60x higher expression, and 22x higher expression even at 10x lower dose. That's not just a "wow-number". It's the commercial point itself: more effect per vector, lower dose requirement, and potentially better safety margin. The poster abstract about the heart is perhaps even more important technically. It not only shows high expression but better targeting: more signal in the heart and less off-target in the liver. In addition, the data points to higher RNA levels without higher AAV genome copy numbers. This supports that the advantage actually lies in the circVec system, not just in better delivery. And perhaps most importantly: they show signs of less cell stress. High expression alone is not enough if the cells are simultaneously pushed too hard. If Circio can combine high expression with lower stress and lower dose, that is exactly the type of platform advantage Big Pharma cares about. The ASGCT data clearly moves circVec further from "promising technology" to "platform with increasingly strong technical validation". That is why this is important. Not because everything is proven. But because more and more pieces are now pointing in the same direction.
·1 t sittenIs it even allowed to use chat gpt and not cite chat gpt?
·1 t sitten · MuokattuReduced cellular stress (UPR) This is very striking: - AAV + high expression = toxicity problem - here we see more expression + less stress This is unusual because the platform seems to increase output WITHOUT increasing cellular burden. This happens extremely rarely - well done, Circio! BUT it is still preclinical. And it is only valuable if it also applies in a functional and clinical context, i.e., we need to see it in CAR-T! DATA is STILL King,- but tonight we celebrate great progress!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
12 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenJust a clip from GPT with the question: can this end in acquisition within 6 months? Short answer: 👉 Yes, this can absolutely end in acquisition 👉 Within 6 months? Possible – but not the most likely without a trigger Let's be completely honest and a bit brutally realistic, as you like it: ⸻ 🧠 Why this CAN become an acquisition What you have here hits several “acquisition signals” Big Pharma looks for: 1. Platform, not just one product * circVec works in heart, CNS, eye * Can be plugged into many pipeline projects 👉 This is exactly what companies like Roche, Novartis and Pfizer buy ⸻ 2. Solves a real problem (AAV dose) * Dose is the #1 issue in gene therapy (toxicity + cost) * Here they show: * 10–60x better effect * Lower dose 👉 This is “holy grail”-type improvement ⸻ 3. Preclinical data is starting to be “too good to ignore” * Consistent across tissues * Better than mRNA-based AAV solutions 👉 This is often the point where: * partnerships start * or acquisitions are considered
- ·1 t sitten · MuokattuVery good abstract and it exudes confidence and trust in the data between the lines. I believe this 'powder' will be supplemented with updated heart 4.0 and CNS data at the presentations themselves. "2 inner and away with them."
- ·1 t sittenIf people don't open their eyes now, there must be something wrong with their cognitive abilities. Surprisingly, the abstracts are bringing us closer and closer to an acquisition. In my view, this is clearly stronger than many seem to understand. Circio is coming to ASGCT with two abstracts: one oral presentation and one poster. The most important thing is not just that they have been selected. The most important thing is what they actually show. The oral presentation is about circVec as a broad AAV platform across eye, heart, and CNS. This is where the platform case lies. If a technology only works in one narrow model, its value is limited. But when the same principle shows effect in multiple tissues, with different setups and administration routes, it starts to resemble something far more valuable. The eye part is particularly strong: over 60x higher expression, and 22x higher expression even at 10x lower dose. That's not just a "wow-number". It's the commercial point itself: more effect per vector, lower dose requirement, and potentially better safety margin. The poster abstract about the heart is perhaps even more important technically. It not only shows high expression but better targeting: more signal in the heart and less off-target in the liver. In addition, the data points to higher RNA levels without higher AAV genome copy numbers. This supports that the advantage actually lies in the circVec system, not just in better delivery. And perhaps most importantly: they show signs of less cell stress. High expression alone is not enough if the cells are simultaneously pushed too hard. If Circio can combine high expression with lower stress and lower dose, that is exactly the type of platform advantage Big Pharma cares about. The ASGCT data clearly moves circVec further from "promising technology" to "platform with increasingly strong technical validation". That is why this is important. Not because everything is proven. But because more and more pieces are now pointing in the same direction.·1 t sittenIs it even allowed to use chat gpt and not cite chat gpt?
- ·1 t sitten · MuokattuReduced cellular stress (UPR) This is very striking: - AAV + high expression = toxicity problem - here we see more expression + less stress This is unusual because the platform seems to increase output WITHOUT increasing cellular burden. This happens extremely rarely - well done, Circio! BUT it is still preclinical. And it is only valuable if it also applies in a functional and clinical context, i.e., we need to see it in CAR-T! DATA is STILL King,- but tonight we celebrate great progress!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 105 | - | - | ||
| 210 | - | - | ||
| 2 035 | - | - | ||
| 34 | - | - | ||
| 1 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
12 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenJust a clip from GPT with the question: can this end in acquisition within 6 months? Short answer: 👉 Yes, this can absolutely end in acquisition 👉 Within 6 months? Possible – but not the most likely without a trigger Let's be completely honest and a bit brutally realistic, as you like it: ⸻ 🧠 Why this CAN become an acquisition What you have here hits several “acquisition signals” Big Pharma looks for: 1. Platform, not just one product * circVec works in heart, CNS, eye * Can be plugged into many pipeline projects 👉 This is exactly what companies like Roche, Novartis and Pfizer buy ⸻ 2. Solves a real problem (AAV dose) * Dose is the #1 issue in gene therapy (toxicity + cost) * Here they show: * 10–60x better effect * Lower dose 👉 This is “holy grail”-type improvement ⸻ 3. Preclinical data is starting to be “too good to ignore” * Consistent across tissues * Better than mRNA-based AAV solutions 👉 This is often the point where: * partnerships start * or acquisitions are considered
- ·1 t sitten · MuokattuVery good abstract and it exudes confidence and trust in the data between the lines. I believe this 'powder' will be supplemented with updated heart 4.0 and CNS data at the presentations themselves. "2 inner and away with them."
- ·1 t sittenIf people don't open their eyes now, there must be something wrong with their cognitive abilities. Surprisingly, the abstracts are bringing us closer and closer to an acquisition. In my view, this is clearly stronger than many seem to understand. Circio is coming to ASGCT with two abstracts: one oral presentation and one poster. The most important thing is not just that they have been selected. The most important thing is what they actually show. The oral presentation is about circVec as a broad AAV platform across eye, heart, and CNS. This is where the platform case lies. If a technology only works in one narrow model, its value is limited. But when the same principle shows effect in multiple tissues, with different setups and administration routes, it starts to resemble something far more valuable. The eye part is particularly strong: over 60x higher expression, and 22x higher expression even at 10x lower dose. That's not just a "wow-number". It's the commercial point itself: more effect per vector, lower dose requirement, and potentially better safety margin. The poster abstract about the heart is perhaps even more important technically. It not only shows high expression but better targeting: more signal in the heart and less off-target in the liver. In addition, the data points to higher RNA levels without higher AAV genome copy numbers. This supports that the advantage actually lies in the circVec system, not just in better delivery. And perhaps most importantly: they show signs of less cell stress. High expression alone is not enough if the cells are simultaneously pushed too hard. If Circio can combine high expression with lower stress and lower dose, that is exactly the type of platform advantage Big Pharma cares about. The ASGCT data clearly moves circVec further from "promising technology" to "platform with increasingly strong technical validation". That is why this is important. Not because everything is proven. But because more and more pieces are now pointing in the same direction.·1 t sittenIs it even allowed to use chat gpt and not cite chat gpt?
- ·1 t sitten · MuokattuReduced cellular stress (UPR) This is very striking: - AAV + high expression = toxicity problem - here we see more expression + less stress This is unusual because the platform seems to increase output WITHOUT increasing cellular burden. This happens extremely rarely - well done, Circio! BUT it is still preclinical. And it is only valuable if it also applies in a functional and clinical context, i.e., we need to see it in CAR-T! DATA is STILL King,- but tonight we celebrate great progress!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 105 | - | - | ||
| 210 | - | - | ||
| 2 035 | - | - | ||
| 34 | - | - | ||
| 1 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt